PARP-1与PARP-2在c-Myc驱动的小鼠B细胞淋巴瘤中作用相反
该研究在Eμ-Myc小鼠模型中探讨PARP-1和PARP-2对c-Myc驱动B细胞淋巴瘤的影响。结果显示敲除PARP-2可预防淋巴瘤发生,而PARP-1缺失加速淋巴瘤生成,两者作用相反,提示选择性PARP-2抑制可能成为c-Myc驱动肿瘤的新治疗策略。
要点
- PARP-2缺失通过加重复制应激和DNA损伤限制c-Myc驱动B细胞扩增,预防淋巴瘤。
- PARP-1缺失诱导促炎反应和调节性T细胞增加,可能促进免疫逃逸而加速淋巴瘤生成。
- 现有PARP抑制剂不能区分PARP蛋白亚型,选择性PARP-2抑制或为c-Myc驱动肿瘤新策略。
核心结论
- PARP-1和PARP-2对c-Myc驱动B细胞淋巴瘤进展发挥相反作用,选择性PARP-2抑制可能代表c-Myc驱动肿瘤的新治疗方向。
研究设计与样本
- 研究采用Eμ-Myc侵袭性B细胞淋巴瘤小鼠模型,通过遗传删除PARP-1或PARP-2比较对淋巴瘤发生的影响。
主要发现
- 遗传删除PARP-2可预防c-Myc驱动B细胞淋巴瘤。
- PARP-1缺陷加速Eμ-Myc小鼠淋巴瘤生成。
- PARP-2缺失加重白血病前Eμ-Myc B细胞复制应激,导致DNA损伤积累和细胞死亡,限制B细胞扩增。
- PARP-1缺陷诱导促炎反应和调节性T细胞增加,可能促进B细胞淋巴瘤免疫逃逸。
临床怎么用
- 提示开发选择性PARP-2抑制剂而非泛PARP抑制剂可能用于c-Myc驱动肿瘤的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the Eμ-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic Eμ-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors.
引用
- Galindo-Campos MA, Lutfi N, Bonnin S, et al. Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice. Blood. 2022. PMID: 34359075. doi:10.1182/blood.2021012805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。